Capula Management’s AbbVie ABBV Stock Holding History

Capula Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.41M	Buy	5,600 +700	+14%	+$151K	0.01%	260
2026 Q1	$1.07M	Buy	4,900 +1,200	+32%	+$266K	0.01%	354
2025 Q4	$845K	Sell	3,700 -3,000	-45%	-$683K	﹤0.01%	313
2025 Q3	$1.55M	Buy	6,700 +4,700	+235%	+$957K	0.01%	294
2025 Q2	$371K	Sell	2,000 -1,300	-39%	-$242K	﹤0.01%	266
2025 Q1	$691K	Buy	+3,300	New	+$642K	﹤0.01%	287
2024 Q4	–	Sell	-2,500	Closed	-$494K	–	365
2024 Q3	$494K	Sell	2,500 -2,600	-51%	-$485K	0.01%	249
2024 Q2	$875K	Buy	+5,100	New	+$845K	0.01%	171
2023 Q4	–	Sell	-6,200	Closed	-$924K	–	290
2023 Q3	$924K	Sell	6,200 -136,500	-96%	-$20M	0.02%	231
2023 Q2	$19.2M	Sell	142,700 -62,300	-30%	-$9.14M	0.47%	35
2023 Q1	$32.7M	Buy	205,000 +48,600	+31%	+$7.43M	0.39%	51
2022 Q4	$25.3M	Buy	156,400 +35,400	+29%	+$5.43M	0.34%	78
2022 Q3	$16.2M	Sell	121,000 -753,500	-86%	-$108M	0.22%	123
2022 Q2	$134M	Buy	874,500 +822,500	+1,582%	+$126M	2.29%	5
2022 Q1	$8.43M	Buy	+52,000	New	+$7.55M	0.12%	149
2021 Q4	–	Sell	-56,100	Closed	-$5.98M	–	170
2021 Q3	$5.98M	Buy	56,100 +36,100	+181%	+$4.12M	0.07%	209
2021 Q2	$2.23M	Sell	20,000 -50,400	-72%	-$5.68M	0.04%	283
2021 Q1	$7.62M	Buy	70,400 +44,100	+168%	+$4.72M	0.15%	157
2020 Q4	$2.82M	Buy	+26,300	New	+$2.53M	0.14%	139
2020 Q3	–	Sell	-155,000	Closed	-$15.2M	–	134
2020 Q2	$15.2M	Buy	155,000 +80,000	+107%	+$7.04M	0.54%	40
2020 Q1	$5.71M	Buy	75,000 +50,000	+200%	+$4.26M	0.21%	144
2019 Q4	$2.21M	Sell	25,000 -112,900	-82%	-$9.37M	0.05%	246
2019 Q3	$10.4M	Buy	+137,900	New	+$9.45M	0.22%	105

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capula Management's ABBV Position: Q2 2026 in Review

Capula Management reduced its AbbVie (ABBV) stake by 50% in Q2 2026, selling an estimated $694K and leaving 3,168 shares worth $797K. The position accounts for ﹤0.01% of the portfolio, ranked #314.

Capula Management first reported a position in ABBV in Q2 2019 and has held it in 19 quarters since. The position peaked at $7.03M in Q1 2020. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Capula Management held 3,168 shares of AbbVie worth $797K as of Q2 2026.
Capula Management sold 3,224 AbbVie shares in Q2 2026, an estimated $694K.
AbbVie made up ﹤0.01% of Capula Management's portfolio in Q2 2026, its #314 holding.
Capula Management first reported a position in AbbVie in Q2 2019 and has held it in 19 quarters since.
Capula Management's AbbVie position peaked at $7.03M in Q1 2020.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.